Ruth Alvarez
Follows a course of treatment past the first month, where most write-ups stop.
Ruth Alvarez writes the long view for This GLP: what the second month feels like, what a plateau does to a dose schedule, and what stopping does. Weight and appetite after discontinuation are part of that beat, because they are the part a reader asks about last and needs first. Most coverage of these drugs ends at the point of purchase, so the questions that matter most to a reader a year in are the ones nobody answers. The reporting leans on trial follow-up data, on what sellers actually tell patients about continuation, and on the parts of the label that describe discontinuation. Nothing here is a clinical opinion, and no credential is claimed for it; it is an account of what has been documented, with each source named.
What they cover
- Weight regain after discontinuation
- Tolerability over the first six months
- Plateaus and dose escalation decisions
- Maintenance dosing and long-term cost
- What continuation actually requires of a patient
- Trial follow-up beyond the primary endpoint